163 related articles for article (PubMed ID: 28653454)
1. Effect of cotrimoxazole prophylaxis on malaria occurrence among HIV-infected adults in West Africa: the MALHIV Study.
Eholié SP; Ello FN; Coffie PA; Héma A; Minta DK; Sawadogo A
Trop Med Int Health; 2017 Sep; 22(9):1186-1195. PubMed ID: 28653454
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study.
Kasirye R; Grosskurth H; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Baisley K
Malar J; 2016 Jul; 15():361. PubMed ID: 27417903
[TBL] [Abstract][Full Text] [Related]
3. Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis.
Ottichilo RK; Polyak CS; Guyah B; Singa B; Nyataya J; Yuhas K; John-Stewart G; Waitumbi JN
J Infect Dis; 2017 Jan; 215(1):88-94. PubMed ID: 28077587
[TBL] [Abstract][Full Text] [Related]
4. Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study.
Kasirye RP; Baisley K; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Grosskurth H
AIDS; 2016 Feb; 30(4):635-44. PubMed ID: 26558729
[TBL] [Abstract][Full Text] [Related]
5. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
[TBL] [Abstract][Full Text] [Related]
6. Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d'Ivoire: a prospective cohort study.
Harouna AM; Amorissani-Folquet M; Eboua FT; Desmonde S; N'Gbeche S; Aka EA; Kouadio K; Kouacou B; Malateste K; Bosse-Amani C; Ahuatchi Coffie P; Leroy V;
BMC Infect Dis; 2015 Aug; 15():317. PubMed ID: 26248711
[TBL] [Abstract][Full Text] [Related]
7. Increased malaria parasitaemia among adults living with HIV who have discontinued cotrimoxazole prophylaxis in Kitgum district, Uganda.
Orishaba P; Kalyango JN; Byakika-Kibwika P; Arinaitwe E; Wandera B; Katairo T; Muzeyi W; Nansikombi HT; Nakato A; Mutabazi T; Kamya MR; Dorsey G; Nankabirwa JI
PLoS One; 2020; 15(11):e0240838. PubMed ID: 33175844
[TBL] [Abstract][Full Text] [Related]
8. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.
Mermin J; Ekwaru JP; Liechty CA; Were W; Downing R; Ransom R; Weidle P; Lule J; Coutinho A; Solberg P
Lancet; 2006 Apr; 367(9518):1256-61. PubMed ID: 16631881
[TBL] [Abstract][Full Text] [Related]
9. Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial.
Polyak CS; Yuhas K; Singa B; Khaemba M; Walson J; Richardson BA; John-Stewart G
PLoS Med; 2016 Jan; 13(1):e1001934. PubMed ID: 26731191
[TBL] [Abstract][Full Text] [Related]
10. Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis.
Mbeye NM; ter Kuile FO; Davies MA; Phiri KS; Egger M; Wandeler G;
Trop Med Int Health; 2014 Sep; 19(9):1057-67. PubMed ID: 25039469
[TBL] [Abstract][Full Text] [Related]
11. Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial.
Anywaine Z; Levin J; Kasirye R; Lutaakome JK; Abaasa A; Nunn A; Grosskurth H; Munderi P;
PLoS One; 2018; 13(12):e0206907. PubMed ID: 30596666
[TBL] [Abstract][Full Text] [Related]
12. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria.
Jegede FE; Oyeyi TI; Abdulrahman SA; Mbah HA; Badru T; Agbakwuru C; Adedokun O
PLoS One; 2017; 12(3):e0174233. PubMed ID: 28346490
[TBL] [Abstract][Full Text] [Related]
13. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.
Losina E; Yazdanpanah Y; Deuffic-Burban S; Wang B; Wolf LL; Messou E; Gabillard D; Seyler C; Freedberg KA; Anglaret X
Antivir Ther; 2007; 12(4):543-51. PubMed ID: 17668563
[TBL] [Abstract][Full Text] [Related]
14. Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV.
Ku SW; Jiamsakul A; Joshi K; Pasayan MKU; Widhani A; Chaiwarith R; Kiertiburanakul S; Avihingsanon A; Ly PS; Kumarasamy N; Do CD; Merati TP; Nguyen KV; Kamarulzaman A; Zhang F; Lee MP; Choi JY; Tanuma J; Khusuwan S; Sim BLH; Ng OT; Ratanasuwan W; Ross J; Wong WW;
J Int AIDS Soc; 2019 Mar; 22(3):e25264. PubMed ID: 30924281
[TBL] [Abstract][Full Text] [Related]
15. Improved survival with co-trimoxazole prophylaxis among people living with HIV/AIDS who initiated antiretroviral treatment in Henan Province, China.
Zhu Q; Wang L; Lin W; Bulterys M; Yang W; Sun D; Cui Z; Kaplan J; Kleinman N; Wei X; Chung J; Wang Z
Curr HIV Res; 2014; 12(5):359-65. PubMed ID: 25426939
[TBL] [Abstract][Full Text] [Related]
16. Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials.
Denoeud-Ndam L; Zannou DM; Fourcade C; Taron-Brocard C; Porcher R; Atadokpede F; Komongui DG; Dossou-Gbete L; Afangnihoun A; Ndam NT; Girard PM; Cot M
J Acquir Immune Defic Syndr; 2014 Feb; 65(2):198-206. PubMed ID: 24220287
[TBL] [Abstract][Full Text] [Related]
17. Impact of cotrimoxazole and insecticide-treated nets for malaria prevention on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review.
Saadani Hassani A; Marston BJ
J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3(Suppl 3):S306-17. PubMed ID: 25768870
[TBL] [Abstract][Full Text] [Related]
18. Burden of asymptomatic malaria, anemia and relationship with cotrimoxazole use and CD4 cell count among HIV1-infected adults living in Gabon, Central Africa.
Bouyou Akotet MK; Koumba Lengongo JV; Ondounda M; Kendjo E; Mongo Delis A; Essomeyo Mebale M; Ndong Ngomo JM; M Bondoukwe NP; Mawili-Mboumba DP; Okome Nkoumou M
Pathog Glob Health; 2018 Mar; 112(2):63-71. PubMed ID: 29161993
[TBL] [Abstract][Full Text] [Related]
19. Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China.
Cheng W; Wu Y; Wen Y; Ma Y; Zhao D; Dou Z; Zhang W; Bulterys M; Zhang F
Bull World Health Organ; 2015 Mar; 93(3):152-60. PubMed ID: 25838611
[TBL] [Abstract][Full Text] [Related]
20. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Côte d'Ivoire.
Anglaret X; Messou E; Ouassa T; Toure S; Dakoury-Dogbo N; Combe P; Mahassadi A; Seyler C; N'Dri-Yoman T; Salamon R;
AIDS; 2003 Mar; 17(4):575-84. PubMed ID: 12598778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
